Ipilimumab with fotemustine in metastatic melanoma

被引：5
|
作者：
Garbe, Claus [1 ]
机构：
[1] Univ Med Ctr, Dept Dermatol, Div Dermatooncol, D-72074 Tubingen, Germany
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 09期
关键词：
DISSEMINATED MALIGNANT-MELANOMA; DACARBAZINE; THERAPY;
D O I：
10.1016/S1470-2045(12)70341-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：851 / 852
页数：3
相关论文
共 50 条
  • [41] Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
    Nyakas, M.
    Aamdal, E.
    Jacobsen, K. D.
    Guren, T. K.
    Aamdal, S.
    Hagene, K. T.
    Brunsvig, P.
    Yndestad, A.
    Halvorsen, B.
    Tasken, K. A.
    Aukrust, P.
    Maelandsmo, G. M.
    Ueland, T.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2019, 197 (01): : 74 - 82
  • [42] Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
    Hodi, F. Stephen
    Lawrence, Donald
    Lezcano, Cecilia
    Wu, Xinqi
    Zhou, Jun
    Sasada, Tetsuro
    Zeng, Wanyong
    Giobbie-Hurder, Anita
    Atkins, Michael B.
    Ibrahim, Nageatte
    Friedlander, Philip
    Flaherty, Keith T.
    Murphy, George F.
    Rodig, Scott
    Velazquez, Elsa F.
    Mihm, Martin C., Jr.
    Russell, Sara
    DiPiro, Pamela J.
    Yap, Jeffrey T.
    Ramaiya, Nikhil
    van den Abbeele, Annick D.
    Gargano, Maria
    McDermott, David
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (07) : 632 - 642
  • [43] Ipilimumab plus temozolomide in metastatic melanoma.
    Patel, S. P.
    Bedikian, A. Y.
    Papadopoulos, N. E.
    Hwu, W.
    Kim, K. B.
    Homsi, J.
    Davies, M. A.
    Woodman, S. E.
    Radvanyi, L. G.
    Woodard, K.
    Mahoney, S.
    Hwu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] PREDICTORS OF SURVIVAL FOR THERAPY WITH IPILIMUMAB IN METASTATIC MELANOMA
    Valpione, S.
    Bazzi, M.
    Piccin, L.
    Pigozzo, J.
    Chiarion-Sileni, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] Retrospective study of the efficacy and safety of fotemustine in 170 patients with metastatic melanoma
    Gonzalez-Larriba, J. L.
    Berrocal, A.
    Cerezuela, P.
    Galan, A.
    Jimenez, J.
    Moreno, A.
    Piulats, J. M.
    Fra, J.
    Crespo, G.
    Gonzalez, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma
    Richard, MA
    Grob, JJ
    Zarrour, H
    Basseres, N
    Bizzari, JP
    Gerard, B
    Bonerandi, JJ
    MELANOMA RESEARCH, 1998, 8 (02) : 170 - 174
  • [47] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
  • [48] Activity of fotemustine in metastatic melanoma: Experience at Milan National Cancer Institute
    Nova, Paola
    Del Vecchio, Michele
    Fusi, Alberto
    Canova, Stefania
    Paleari, Daniela
    Verzoni, Elena
    Bajetta, Emilio
    ANNALS OF ONCOLOGY, 2005, 16 : 57 - 58
  • [49] LOCAL TREATMENT OF CUTANEOUS AND SUBCUTANEOUS METASTATIC MALIGNANT-MELANOMA WITH FOTEMUSTINE
    SCHALLREUTER, KU
    WOOD, JM
    MENSING, H
    BREITBART, EW
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 29 (02) : 167 - 171
  • [50] Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib
    Niederkorn, Anna
    Wackernagel, Werner
    Artl, Monika
    Schwantzer, Gerold
    Aigner, Birgit
    Richtig, Erika
    ACTA OPHTHALMOLOGICA, 2014, 92 (08) : e696 - e697
12345